Weekly news updates are currently posted on the Internet site and sent out via
e-blast to provide up-to-date information on what has been covered in the news regarding lung cancer in the previous week.
Would you like to receive our newsletter directly to your inbox?
Lung Cancer News
Week Ending August 5, 2019
Underlying Pathway in Lung Cancer Could Identify Appropriate Targeted Treatments
“Research has uncovered 2 pathways through which lung adenocarcinoma can develop, and that knowledge could help target treatments to patients who will benefit the most, according to a new study published in Cancer Cell.”
Q&A: Detecting lung cancer early
“Q: How can I detect lung cancer early?”
Can Deep Learning Algorithms Speed Up Lung Cancer Care?
“A deep learning approach to assessing cancer outcomes appears feasible, according to results of a study in patients with lung cancer. Machine curation yielded similarly accurate assessments of progression and times to improvement and response compared with human counterparts. This development could speed up oncology care processes.”
Lung Cancer Foundation of America introduces Hope With Answers℠: videos by patients, for patients and their families
“Get hope with answers about the latest treatments and research from patients living with lung cancer as they interview top doctors”
20% of lung cancer deaths are preventable: Here’s what you can do
“Well-informed lung cancer screening recommendations for high-risk patients offer them the best hope to catch the disease early, providing the best chance for effective treatment.”
Amgen results beat estimates, lung cancer trial planned
“Amgen on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped its results exceed Wall Street forecasts.”
Dr. Goldberg on Immune/Targeted Therapy Combos in Oncogene-Driven Lung Cancer
“Sarah B. Goldberg, MD, MPH, associate professor of internal medicine, Yale School of Medicine and Yale Cancer Center, discusses the combination of immunotherapy and targeted therapy for the treatment of patients with oncogene-driven lung cancer.”
Leading Oncologist Highlights Key Lung Cancer Advances
“There has been a heavy focus on individualization in lung cancer treatment over the last 10 years, explained Konstantinos Arnaoutakis, MD, touting advances with immunotherapy as well as targeted therapies for patients with EGFR- and ALK-positive disease.”
More Is Needed for Immunotherapy in Lung Cancer
“Immunothearpy generated landmark change in the treatment of lung cancer, but there are still some pressing issues and unanswered questions that need to be addressed, according to Fred R. Hirsch, MD, PhD, executive director at the Center for Thoracic Oncology in The Tisch Cancer Institute at Mount Sinai (TCI) and the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai.”